Plant-Based Vaccine for Livestock: Key Points to Unleash Platform Translation in Developing Countries

Abstract

Ten years ago the first plant-based vaccine was licensed (DowAgrosciences). It was only 20 years after the first report of a recombinant protein obtained through plant transformation technology. Back then, this vaccine was perceived as the first of an unlimited list of innovative products of a flourishing platform. Unexpectedly, since then, no other veterinary product based on plant molecular pharming (PMP) has reached the market. This review will reflect a trans-disciplinary view of the status and challenges that the molecular farming platform faces to become a strategic solution for the agroindustrial sector of developing countries.